Clinical Trials in Acute Lymphoblastic Leukaemia (ALL)


Trial Title


Trial Description


More information (external website)




The aims of this trial are to see if changing the standard treatment for children and young people with ALL or LBL will reduce side effects and help stop their disease from coming back. People aged 1 – 24 years old are eligible.




This trial is looking at combining selumetinib with dexamethasone for children and adults with acute lymphoblastic leukaemia (ALL).

It is open to people with ALL that has come back after treatment (relapsed) or has continued to get worse during treatment (refractory). 





The aim of this study is to find a standard treatment for ALL in adults over the age of 60. Researchers can then use this in the future as a comparison when looking at any new treatments in clinical trials.